ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 0950

Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde (MAA) Modified Vimentin Induces Fibrotic Lung Changes

Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0923

Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde Modified Vimentin Induces Post-Translational Protein Modifications and Extracellular Matrix Deposition in Heart Tissues

Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 1204

Immunobased Profiling of Knee Osteoarthritis Patients to Predict Response to Regenerative Treatment with Autologous Blood-derivative Platelet-Rich Plasma Injection

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 1009

Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1514

Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1038

IMPACT (Impact of eMbedded Pharmacists in an Academic Center sTudy)

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 1035

Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 1032

Impact of a Coordinated Care Model for Addressing Rheumatoid Arthritis and Associated Comorbidities

Healthcare Disparities in Rheumatology Poster II

10:30AM-12:30PM: Abstract Number: 1510

Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1146

Impact of COVID-19 on Myositis Testing Trends

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1437

Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1124

Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1319

Impact of Illness Cognition and Self-Esteem on Quality of Life in Reproductive-Age Women with Autoimmune Rheumatic Diseases

Psychology/Social Sciences Poster – ARP

10:30AM-12:30PM: Abstract Number: 1582

Impact of Immunosuppressive Treatment on Development and Survival in Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)

Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1360

Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment

RA – Diagnosis, Manifestations, & Outcomes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].